Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Minerva Neurosciences, Inc. (NERV) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/13/2022 8-K Investor presentation
Docs: "Presentation of Minerva Neurosciences, Inc.",
"Presentation of Minerva Neurosciences, Inc."
01/05/2022 8-K Investor presentation
Docs: "Presentation of Minerva Neurosciences, Inc.",
"Presentation of Minerva Neurosciences, Inc."
12/08/2021 8-K Quarterly results
06/05/2020 8-K Investor presentation
Docs: "Corporate Presentation"
04/01/2020 8-K Investor presentation
Docs: "Company Presentation",
"Company Presentation"
03/22/2018 8-K Investor presentation
Docs: "Corporate Presentation dated March 2018",
"Corporate Presentation dated March 2018"
02/21/2018 8-K Investor presentation
Docs: "Investor Presentation dated February 2018",
"Investor Presentation dated February 2018"
01/08/2018 8-K Investor presentation
Docs: "Investor Presentation dated January 2018",
"Investor Presentation dated January 2018"
05/15/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
01/06/2017 8-K Form 8-K - Current report
10/26/2016 8-K Form 8-K - Current report
06/13/2016 8-K Investor presentation
Docs: "Investor Presentation dated June 2016"
06/06/2016 8-K Form 8-K - Current report
09/24/2015 8-K Investor presentation
Docs: "MINERVA NEUROSCIENCES PROVIDES UPDATE ON CLINICAL DEVELOPMENT PROGRAM WITH MIN-202, SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST Patient recruitment ongoing in trials in insomnia disorder and adjunctive major depressive disorder Waltham, MA, September 24, 2015 - Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today provided an update on two ongoing clinical trials with MIN-202 , a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV. Patient recruitment is ongoing in both trials, which include a Phase 2a trial in insomnia disorder and a Phase 1b trial in adjunctive major depressive disorder . “We are pleased with the progress that is being...",
"Presentation of the Company"
03/26/2015 8-K Investor presentation
Docs: "Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results"
03/03/2015 8-K Investor presentation
Docs: "Investor Presentation dated March 2015"
11/06/2014 8-K Investor presentation, Quarterly results
Docs: "Minerva Neurosciences Reports Third Quarter 2014 Financial Results"
09/04/2014 8-K Investor presentation
Docs: "Presentation of the Company"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy